Table 4.
Metabolites altered after purified rhodomyrtone treatment of Streptococcus pneumoniae.
| Metabolite | Strain | MW (g/mol) | Retention time (min) | Precursor ion (m/z) | Fold changea | Related pathway or function |
|---|---|---|---|---|---|---|
| Metabolites with decreased abundance | ||||||
| Thymidine monophosphate | R6, TIGR4 | 322.057 | 2.7 | 321.049 | 13.49*, 1.71 | Nucleic acid biosynthesis |
| L-Tryptophan | R6, TIGR4 | 204.090 | 4.8 | 205.097 | 1.34*, 1.70* | Amino acid biosynthesis |
| Uridine 5′-diphosphoglucuronic acid | R6, TIGR4 | 580.034 | 1.1 | 579.028 | 1.69*, 3.00* | Capsule synthesis |
| N-Acetyl-L-glutamic acid | R6, TIGR4 | 189.064 | 1.8 | 188.056 | 2.11*, 1.09 | Urea cycle |
| UDP-glucose | R6, TIGR4 | 566.055 | 1.1 | 565.047 | 1.31, 1.27* | Capsule synthesis |
| Hypoxanthine | R6, TIGR4 | 136.039 | 1.6 | 137.046 | 1.02, 2.21* | Nucleic acid biosynthesis |
| Deoxyinosine | R6 | 252.086 | 3.7 | 251.077 | INFb | Nucleic acid biosynthesis |
| Guanosine | R6, TIGR4 | 283.092 | 2.2 | 284.099 | 1.01, INF | Nucleic acid biosynthesis |
| Inosine | R6 | 268.081 | 3.3 | 267.074 | 1.07 | Nucleic acid biosynthesis |
| D-(+)-3-Phenyllactic acid | R6, TIGR4 | 166.063 | 6.6 | 165.054 | INF, INF | Antimicrobial compound |
| L-Aspartic Acid | TIGR4 | 133.038 | 1.0 | 132.030 | 1.35 | Amino acid biosynthesis |
| N-Acetyl-DL-methionine | TIGR4 | 191.062 | 5.1 | 190.054 | 4.77* | Oxidative stress response |
| Acetyl-CoA | TIGR4 | 809.126 | 5.0 | 403.556 | 1.98* | Lipid metabolism, activating intermediate molecule |
| Raffinose | R6 | 504.169 | 1.2 | 503.162 | 2.03* | Raffinose/stachyose/melibiose transport system |
| Deoxyadenosine monophosphate | TIGR4 | 331.068 | 1.6 | 332.075 | 1.04 | Nucleic acid biosynthesis |
| Palmitic acid | R6, TIGR4 | 256.240 | 0.4 | 257.247 | 1.09, 1.38 | Lipid biosynthesis |
| UDP-N-acetyl-D-galactosamine | TIGR4 | 607.082 | 1.2 | 606.074 | 3.12* | Capsule synthesis |
| Pyroglutamic acid | R6 | 129.043 | 1.5 | 128.035 | 3.77* | Amino acid metabolism |
| Metabolites with increased abundance | ||||||
| Guanosine monophosphate | R6, TIGR4 | 363.058 | 1.5 | 362.052 | 3.38*, 2.32* | Nucleic acid biosynthesis |
| L-Tyrosine | R6 | 181.074 | 1.8 | 180.067 | 1.08 | Amino acid biosynthesis |
| Uridine monophosphate | R6, TIGR4 | 580.034 | 1.1 | 579.028 | 4.73*, 1.37* | Nucleic acid biosynthesis |
| D-Ribulose 5-phosphate | R6 | 230.019 | 0.7 | 229.012 | 1.05 | Pentose phosphate pathway |
| D-Glucose 6-phosphate | R6, TIGR4 | 260.030 | 0.7 | 259.023 | 1.71, 5.25* | Glycolysis |
| Cyclic adenosine diphosphate ribose | R6, TIGR4 | 541.061 | 1.4 | 540.055 | 2.85*, 1.04 | Calcium signaling |
| L-Glutamic acid | R6, TIGR4 | 147.053 | 0.7 | 146.046 | 1.37, 1.44* | Amino acid biosynthesis |
| L-Phenylalanine | R6 | 165.079 | 3.5 | 166.086 | 1.69* | Amino acid biosynthesis |
aThe fold change values represent the ratio between control and rhodomyrtone treatment for metabolites with decreased abundance, or the ratio between the rhodomyrtone treatment and the control for metabolites with increased abundance. Statistical significance of the analysis under the Student’s t-test is indicated as *(p < 0.05). bINF means that the metabolite was not detected in the rhodomyrtone-treated samples.